Curaleaf Holdings, Inc. (OTCMKTS:CURLF - Get Free Report)'s stock price traded up 3.8% during trading on Monday . The company traded as high as $3.04 and last traded at $2.98. 344,140 shares were traded during mid-day trading, a decline of 67% from the average session volume of 1,058,454 shares. The stock had previously closed at $2.87.
Analyst Ratings Changes
A number of research analysts recently commented on the stock. Canaccord Genuity Group raised shares of Curaleaf to a "strong-buy" rating in a report on Thursday, October 9th. Cormark raised shares of Curaleaf from a "hold" rating to a "moderate buy" rating in a report on Friday, August 8th. Two equities research analysts have rated the stock with a Strong Buy rating, According to MarketBeat, the stock has an average rating of "Strong Buy".
Read Our Latest Stock Report on Curaleaf
Curaleaf Trading Up 3.8%
The company has a quick ratio of 0.70, a current ratio of 1.47 and a debt-to-equity ratio of 1.00. The firm has a market cap of $2.00 billion, a P/E ratio of -9.31 and a beta of 0.71. The company's 50 day simple moving average is $2.89 and its 200-day simple moving average is $1.66.
Curaleaf (OTCMKTS:CURLF - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.01. Curaleaf had a negative net margin of 18.08% and a negative return on equity of 14.61%. As a group, research analysts predict that Curaleaf Holdings, Inc. will post -0.25 earnings per share for the current fiscal year.
Curaleaf Company Profile
(
Get Free Report)
Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Curaleaf, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curaleaf wasn't on the list.
While Curaleaf currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.